SteadyMed Therapeutics Company Profile

01:53 EDT 22nd September 2018 | BioPortfolio

SteadyMed Therapeutics, Inc. is a private, venture funded, Drug Delivery Therapeutics Company who are leaders in the development and commercialization of prefilled, size efficient and disposable patch pump technology.

SteadyMed Therapeutics family of PatchPumps can be customized to deliver liquid drugs, including biologics, with a wide range of volumes and viscosities, in a consistent and controllable manner.

SteadyMed Therapeutics is focused on becoming a ‘Commercial Drug Delivery Therapeutics Company’ by leveraging the sustainable cost and technological competitive advantages of their PatchPump® platform to create a family of products that benefit patients in target markets, which represent the highest value to risk ratios. 


2410 Camino Ramon, Suite 285
San Ramon


Phone: +1 (925) 309 7077

News Articles [733 Associated News Articles listed on BioPortfolio]

United Therapeutics to purchase SteadyMed in $216m deal

US-based biotechnology company United Therapeutics has signed a definitive merger agreement to buy SteadyMed for a total consideration of $216m,...Read More... The post United Therapeutics to purchase...

United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed

Drug developer SteadyMed has been building momentum to take on the established seller of a therapy for a rare lung disease. But the rivalry could be over before it even started. Instead of competing a...

SteadyMed set to be acquired by United Therapeutics

Shares in specialty Israeli pharma SteadyMed closed 77% up at $4.70 on Monday with the news that it is…

United Therapeutics buys SteadyMed for $216m

SteadyMed was founded in the Zisapel family's RAD Biomed incubator and although today under US management much of the company's development is carried out in its Rehovot offices.

United Therapeutics Strikes Deal for SteadyMed to Bolster PAH Pipeline

Shares of SteadyMed Ltd. have skyrocketed more than 77 percent in premarket trading today after United Therapeutics announced it will acquire the company for a total of $216 million, including $75 mil...

United Therapeutics to acquire SteadyMed

United Therapeutics Corp. is paying $4.46 per share in cash (a 55% premium) to acquire SteadyMed Ltd. United Therapeutics will also shell out $2.63 per share in cash based on a commercialization miles...

United Therapeutics to Acquire SteadyMed for Up to $216M

United Therapeutics has agreed to acquire SteadyMed Therapeutics for up to $216 million, the companies said today, in a deal designed to absorb a potential competitor with which the would-be buyer has...

M&As this week: United Therapeutics, Par Formulations, Endo Ventures

United Therapeutics Corporation has agreed to acquire SteadyMed for $216m. United Therapeutics will purchase SteadyMed for $4.46 a share in...Read More... The post M&As this week: United Therapeu...

PubMed Articles [436 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Clinical Trials [154 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1256 Associated Companies listed on BioPortfolio]

SteadyMed Therapeutics

SteadyMed Therapeutics, Inc. is a private, venture funded, Drug Delivery Therapeutics Company who are leaders in the development and commercialization of prefilled, size efficient and disposable pat...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "SteadyMed Therapeutics" on BioPortfolio

We have published hundreds of SteadyMed Therapeutics news stories on BioPortfolio along with dozens of SteadyMed Therapeutics Clinical Trials and PubMed Articles about SteadyMed Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SteadyMed Therapeutics Companies in our database. You can also find out about relevant SteadyMed Therapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Corporate Database Quicklinks

Searches Linking to this Company Record